# ImmunityBio, Inc. (IBRX) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from ImmunityBio, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/IBRX/mda/fy2025/): filed 2026-02-23; accession 0001326110-26-000030 (https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/ibrx-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/IBRX/mda/fy2024/): filed 2025-03-03; accession 0001326110-25-000033 (https://www.sec.gov/Archives/edgar/data/1326110/000132611025000033/ibrx-20241231.htm)
- [FY 2023 MD&A](/company/IBRX/mda/fy2023/): filed 2024-03-19; accession 0001326110-24-000037 (https://www.sec.gov/Archives/edgar/data/1326110/000132611024000037/ibrx-20231231.htm)
- FY 2022: filed 2023-03-01; accession 0001326110-23-000018 (https://www.sec.gov/Archives/edgar/data/1326110/000132611023000018/ibrx-20221231.htm); MD&A text quarantined because Item 7 boundaries were low-confidence; no filing narrative is published for this year.
- FY 2021: filed 2022-03-01; accession 0001326110-22-000011 (https://www.sec.gov/Archives/edgar/data/1326110/000132611022000011/ibrx-20211231.htm); MD&A text quarantined because Item 7 boundaries were low-confidence; no filing narrative is published for this year.

Back to /company/IBRX/